Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes

Authors:

Abstract
More than 30 million individuals (10%) in the US have type 2 diabetes (T2D), with a higher prevalence—more than 1 in 4—among adults aged 65 years or older.1 Type 2 diabetes is associated with a 35% to 60% relative increase in the risk of developing atrial fibrillation (AF) or atrial flutter (collectively referred to as AF).2-4 Compared with T2D alone, the presence of comorbid T2D and new-onset AF carries a 3.8-fold increased risk for heart failure (HF) and a 2.7-fold increased risk for all-cause mortality.5 Among patients older than 65 years, 27% develop AF in 10 years.6 Owing to the high risk of developing AF, preventing this condition in older patients with T2D is an important goal.

This publication has 64 references indexed in Scilit: